Tracy Timothy S, Venkataramanan Raman, Glover Douglas D, Caritis Steve N
Department of Experimental and Clinical Pharmacology and Center of Excellence in Women's Health, University of Minnesota, Minneapolis, Minn, USA.
Am J Obstet Gynecol. 2005 Feb;192(2):633-9. doi: 10.1016/j.ajog.2004.08.030.
The purpose of this study was to determine whether drug metabolism (CYP1A2, CYP2D6 and CYP3A) activity varies in the pregnant state compared with the nonpregnant state.
Subjects were studied at 14 to18 weeks of gestation, 24 to 28 weeks of gestation, and 36 to 40 weeks of gestation and again at 6 to 8 weeks after the delivery. Twenty-five subjects completed all 4 study periods and had evaluable data. Salivary caffeine clearance was used as a measure of CYP1A2 activity; dextromethorphan O- and N-demethylation were used to assess CYP2D6 and CYP3A activity, respectively.
CYP1A2 activity was significantly reduced at all periods of the pregnancy as compared with the postpartum period during the first (-32.8% +/- 22.8%), second (-48.1% +/- 27%), and third periods (-65.2% +/- 15.3%), respectively. In contrast, CYP2D6 activity was increased significantly throughout the pregnancy (25.6% +/- 58.3% at 14-18 weeks of gestation, 34.8% +/- 41.4% at 24-28 weeks of gestation, and 47.8% +/- 24.7% at 36-40 weeks of gestation) as compared with the postpartum period. CYP3A activity was consistently, significantly increased (35%-38%) during all stages of the pregnancy.
Opposing changes in drug metabolism occur during pregnancy, with CYP1A2 activity decreased and CYP2D6 and CYP3A activities increased. The direction of dosing adjustments during pregnancy will depend on the drug and the enzyme that is responsible for its metabolism.
本研究旨在确定与非孕期相比,孕期药物代谢(CYP1A2、CYP2D6和CYP3A)活性是否存在差异。
对受试者在妊娠14至18周、24至28周、36至40周时进行研究,并在产后6至8周再次进行研究。25名受试者完成了所有4个研究阶段并拥有可评估数据。唾液咖啡因清除率用作CYP1A2活性的指标;右美沙芬O-去甲基化和N-去甲基化分别用于评估CYP2D6和CYP3A活性。
与产后阶段相比,妊娠各阶段CYP1A2活性均显著降低,第一阶段(-32.8%±22.8%)、第二阶段(-48.1%±27%)和第三阶段(-65.2%±15.3%)。相比之下,与产后阶段相比,整个孕期CYP2D6活性显著增加(妊娠14至18周时为25.6%±58.3%,妊娠24至28周时为34.8%±41.4%,妊娠36至40周时为47.8%±24.7%)。孕期所有阶段CYP3A活性持续显著增加(35%-38%)。
孕期药物代谢发生相反变化,CYP1A2活性降低,CYP2D6和CYP3A活性增加。孕期给药调整的方向将取决于药物及其代谢所涉及的酶。